Project Grant R41HL178190
Award Date
7/15/25
Completion Date
12/31/26
Dollars Obligated
$395K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Cutcath LLC (FWQAVYD1DMK4)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $413,595 Project Grant to Unandup, LLC, a medical technology firm based in St. Louis, Missouri. The grant will fund the development of a magnetic rotational atherectomy platform to debulk severely calcified coronary lesions and improve percutaneous coronary intervention procedures. Key innovations include the use of magnetic fields to control the atherectomy...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,751 to Third Coast Dynamics, Inc. to develop an artificial intelligence-based platform called "TCDFLOW" that can derive 4D hemodynamic data from routine clinical anatomic images. This will address limitations of current 4D flow MRI techniques, which require specialized equipment and expertise, by enabling the...
This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, provides $920,176 under the Cardiovascular Diseases Research program to develop a smart aspiration catheter with fiber optic pressure sensors for mechanical thrombectomy procedures to treat acute ischemic stroke. The catheter will be designed, prototyped and validated at Worcester Polytechnic Institute to provide real-time data to interventionalists on the interaction...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is for the development of an endovascular prosthetic graft device that integrates nitric oxide (NO)-releasing polymer technology. The goal is to create a device that can reduce the incidence of infection, neointimal proliferation, and thrombosis - the three main clinical complications associated with current endovascular stent grafts. The total funding...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This federal Project Grant award of $790,738, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and evaluate the Thoraflush, a proactive clot-preventing cardiac chest tube that utilizes dual irrigation technology to maintain drainage patency. The key objectives are to: 1) Optimize the Thoraflush's efficacy in maintaining drainage patency using an in vitro mediastinum blood coagulation model, and...